(MNTL) Tema Neuroscience Mental - Ratings and Ratios
Exchange: NASDAQ •
Country: USA •
Currency: USD •
Type: Etf •
ISIN: US87975E8755
Brain, Treatment, Disasters, Mental, Disorders, Neurology, Pharmaceuticals
Description: MNTL Tema Neuroscience Mental
Under normal circumstances, the Tema Neuroscience and Mental Health ETF seeks to achieve its investment objective by investing at least 80% of its net assets, which include borrowings for investment purposes, in neuroscience and mental health companies. A company is generally considered to be a neuroscience or mental health company that derives at least 50% of revenues from neuroscience or neurology-related diseases, or mental health. The fund is non-diversified.
Additional Sources for MNTL ETF
News:
Wall Street Journal |
Benzinga |
Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle
MNTL ETF Overview
| Market Cap in USD | 10m |
| Category | Health |
| TER | 0.75% |
| IPO / Inception | 2024-01-22 |
MNTL ETF Ratings
| Growth Rating | -41.4 |
| Fundamental | - |
| Dividend Rating | 4.30 |
| Rel. Strength | -23.6 |
| Analysts | - |
| Fair Price Momentum | 20.40 USD |
| Fair Price DCF | - |
MNTL Dividends
| Dividend Yield 12m | 1.07% |
| Yield on Cost 5y | 1.02% |
| Annual Growth 5y | -100.00% |
| Payout Consistency | 100.0% |
| Payout Ratio | % |
MNTL Growth Ratios
| Growth Correlation 3m | 50.5% |
| Growth Correlation 12m | -89.6% |
| Growth Correlation 5y | -50.2% |
| CAGR 5y | -5.73% |
| CAGR/Max DD 5y | -0.22 |
| Sharpe Ratio 12m | -0.12 |
| Alpha | -26.58 |
| Beta | 0.962 |
| Volatility | 17.05% |
| Current Volume | 0k |
| Average Volume 20d | 0.1k |
| Stop Loss | 22.3 (-3.7%) |
What is the price of MNTL shares?
As of July 12, 2025, the stock is trading at USD 23.15 with a total of 24 shares traded.
Over the past week, the price has changed by +2.49%, over one month by +1.10%, over three months by +11.25% and over the past year by -13.47%.
As of July 12, 2025, the stock is trading at USD 23.15 with a total of 24 shares traded.
Over the past week, the price has changed by +2.49%, over one month by +1.10%, over three months by +11.25% and over the past year by -13.47%.
Is Tema Neuroscience Mental a good stock to buy?
Probably not. Based on ValueRay´s Analyses, Tema Neuroscience Mental (NASDAQ:MNTL) is currently (July 2025) not a good stock to buy. It has a ValueRay Growth Rating of -41.42 and therefor a somwhat technical negative rating according to historical growth.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of MNTL is around 20.40 USD . This means that MNTL is currently overvalued and has a potential downside of -11.88%.
Probably not. Based on ValueRay´s Analyses, Tema Neuroscience Mental (NASDAQ:MNTL) is currently (July 2025) not a good stock to buy. It has a ValueRay Growth Rating of -41.42 and therefor a somwhat technical negative rating according to historical growth.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of MNTL is around 20.40 USD . This means that MNTL is currently overvalued and has a potential downside of -11.88%.
Is MNTL a buy, sell or hold?
Tema Neuroscience Mental has no consensus analysts rating.
Tema Neuroscience Mental has no consensus analysts rating.
What are the forecasts for MNTL share price target?
According to our own proprietary Forecast Model, MNTL Tema Neuroscience Mental will be worth about 23.9 in July 2026. The stock is currently trading at 23.15. This means that the stock has a potential upside of +3.28%.
According to our own proprietary Forecast Model, MNTL Tema Neuroscience Mental will be worth about 23.9 in July 2026. The stock is currently trading at 23.15. This means that the stock has a potential upside of +3.28%.
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | - | - |
| Analysts Target Price | - | - |
| ValueRay Target Price | 23.9 | 3.3% |